Welcome to our dedicated page for Surmodics SEC filings (Ticker: SRDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug-coated balloons that release therapy in seconds, hydrophilic coatings that keep catheters moving smoothly—Surmodics invents the invisible layers that make modern cardiovascular devices possible. Unfortunately, its regulatory paperwork is almost as intricate as its science. Whether you’re hunting for segment profit in a 10-K or scanning EDGAR for Surmodics insider trading Form 4 transactions, the process is slow. Many professionals end up Googling “Surmodics quarterly earnings report 10-Q filing” or “Surmodics Form 4 insider transactions real-time” just to locate one number. If that’s you, our page delivers Surmodics SEC filings explained simply and streamlines Surmodics earnings report filing analysis.
Stock Titan’s AI reads every word the instant it hits EDGAR, then translates jargon into plain language. Need understanding Surmodics SEC documents with AI? We flag risk factors, chart revenue shifts, and highlight R&D spending inside a Surmodics annual report 10-K simplified to essentials. Real-time alerts ensure Surmodics executive stock transactions Form 4 never slip past you. For governance checks, our platform links every Surmodics proxy statement executive compensation table to prior years, and when surprises strike we provide Surmodics 8-K material events explained within minutes.
With comprehensive coverage of all filing types and AI-powered summaries you can:
- Compare quarter-over-quarter coating and whole-product revenue without opening spreadsheets
- Monitor insider activity before material announcements
- See how new FDA milestones might reshape guidance
Every 10-K, 10-Q, 8-K, S-1 and Form 4 appears here in real time, backed by expert analysis that makes complex documents clear. Skip the download cycle—get decisive insights faster.
Surmodics (SRDX) Q3 FY25 (period ended 30 Jun 2025) shows mixed performance. Total revenue slipped 3% YoY to $29.6 million as Medical Device sales softened 11% while In Vitro Diagnostics rose 6%. Operating loss was roughly flat at $5.2 million; net loss narrowed to $5.3 million (-$0.37 per share) from $7.6 million. For the nine-month period, revenue fell 6% to $87.6 million and net loss widened to $14.2 million.
Cash & liquidity: Cash and equivalents dropped to $26.3 million (vs $36.1 million at FY-end) after negative operating cash flow of $5.5 million. Long-term debt remains $29.7 million, giving net cash of -$3.4 million. Equity totals $111.3 million against total liabilities of $58.5 million.
Operational highlights: Commercial shipments of the SurVeil drug-coated balloon to Abbott continued; Pounce LP and XL thrombectomy systems and Sublime microcatheters completed limited evaluations and moved to full launch. A June cyber incident generated $1.9 million in costs, of which $1.7 million is expected to be recovered via insurance.
Strategic events: Shareholders approved the $43-per-share cash merger with BCE Parent (GTCR) on 13 Aug 2024, but the FTC filed suit on 6 Mar 2025 to block the deal. Surmodics has incurred $10.1 million of merger-related expenses YTD. Closing is subject to litigation outcome and other customary conditions.
On 8 Aug 2025 Surmodics, Inc. (SRDX) filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1, but the filing itself contains no revenue, EPS, balance-sheet or guidance figures. The disclosure falls under Item 2.02 (Results of Operations and Financial Condition) and is expressly marked as “furnished,” not “filed,” which limits Section 18 Exchange Act liability. Aside from the exhibit list and standard representations, the document offers no additional financial data or strategic commentary.
Trium Capital LLP, a United Kingdom-based investment adviser, filed a Schedule 13G on 15 July 2025 reporting ownership of 716,783 shares of Surmodics, Inc. (SRDX), equal to 5.01 % of the company’s outstanding common stock. Trium has sole voting and dispositive power over the entire position and no shared authority with other parties. Because the filing is a Schedule 13G—rather than an activist 13D—the stake is declared to be held in the ordinary course of business, with no intent to influence control of Surmodics.
The disclosure moves Trium across the 5 % reporting threshold, adding another institutional holder to Surmodics’ register. While the passive nature of the investment means limited governance impact, heightened institutional ownership can improve liquidity, expand research coverage, and serve as a soft vote of confidence in Surmodics’ outlook. There is, however, no information on purchase price, timing of accumulation, or future trading plans, so market impact should be viewed as modest and primarily informational.
FAQ
What is the current stock price of Surmodics (SRDX)?
What is the market cap of Surmodics (SRDX)?
